Literature DB >> 31407167

Risk factors and prognostic significance of lateral pelvic lymph node metastasis in advanced rectal cancer.

Yukiharu Hiyoshi1, Yuji Miyamoto1, Yuki Kiyozumi1, Kojiro Eto1, Yohei Nagai1, Masaaki Iwatsuki1, Shiro Iwagami1, Yoshifumi Baba1, Naoya Yoshida1, Hideo Baba2.   

Abstract

BACKGROUND: The aim of this study was to elucidate the risk factors for and prognostic value of lateral pelvic lymph node (LPLN) metastasis in advanced rectal cancer patients, including those with stage IV disease.
METHODS: The treatment outcomes of 78 patients with advanced rectal cancer, the lower margin of which was located at or below the peritoneal reflection, who underwent curative-intent surgery with bilateral LPLN dissection from 2005 to 2018 were retrospectively analyzed.
RESULTS: In total, 78 rectal cancer patients, including 13 patients with stage IV tumors, 9 patients (11.5%) had LPLN metastasis. A multivariate analysis to identify preoperative clinical factors associated with LPLN metastasis showed that tumor location (below the peritoneal reflection: Rb), LPLN metastasis on preoperative imaging and distant metastasis were independent predictors of LPLN metastasis. In addition, metastasis at the regional lymph nodes in the mesorectum was significantly associated with LPLN metastasis. Both the disease-free survival (DFS) and cancer-specific survival (CSS) of patients with LPLN metastasis were significantly worse in comparison to patients without LPLN metastasis, and the CSS of stage IV patients with LPLN metastasis was significantly worse in comparison to stage IV patients without LPLN metastasis.
CONCLUSIONS: Tumor location (Rb), LPLN metastasis on preoperative imaging and distant metastasis were risk factors for LPLN metastasis. The prognosis of rectal cancer patients with LPLN metastasis is poor. There may not be the indication of LPLN dissection in stage IV lower rectal cancer except cases having complaints due to LPLN metastasis.

Entities:  

Keywords:  Lateral pelvic lymph node; Metastasis; Prognosis; Rectal cancer

Mesh:

Year:  2019        PMID: 31407167     DOI: 10.1007/s10147-019-01523-w

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  32 in total

1.  Preoperative versus postoperative chemoradiotherapy for rectal cancer.

Authors:  Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab
Journal:  N Engl J Med       Date:  2004-10-21       Impact factor: 91.245

2.  Feasibility of Laparoscopic Total Mesorectal Excision with Extended Lateral Pelvic Lymph Node Dissection for Advanced Lower Rectal Cancer after Preoperative Chemoradiotherapy.

Authors:  Atsushi Ogura; Takashi Akiyoshi; Toshiya Nagasaki; Tsuyoshi Konishi; Yoshiya Fujimoto; Satoshi Nagayama; Yosuke Fukunaga; Masashi Ueno; Hiroya Kuroyanagi
Journal:  World J Surg       Date:  2017-03       Impact factor: 3.352

3.  Indication and benefit of pelvic sidewall dissection for rectal cancer.

Authors:  Kenichi Sugihara; Hirotoshi Kobayashi; Tomoyuki Kato; Takeo Mori; Hidetaka Mochizuki; Shingo Kameoka; Kazuo Shirouzu; Tetsuichiro Muto
Journal:  Dis Colon Rectum       Date:  2006-11       Impact factor: 4.585

4.  Potential prognostic benefit of lateral pelvic node dissection for rectal cancer located below the peritoneal reflection.

Authors:  Hideki Ueno; Hidetaka Mochizuki; Yojiro Hashiguchi; Megumi Ishiguro; Masayoshi Miyoshi; Yoshiki Kajiwara; Taichi Sato; Hideyuki Shimazaki; Kazuo Hase
Journal:  Ann Surg       Date:  2007-01       Impact factor: 12.969

5.  Incidence and prognostic significance of lateral lymph node metastasis in patients with advanced low rectal cancer.

Authors:  M Ueno; M Oya; K Azekura; T Yamaguchi; T Muto
Journal:  Br J Surg       Date:  2005-06       Impact factor: 6.939

6.  Technical feasibility of laparoscopic lateral pelvic lymph node dissection for patients with low rectal cancer after concurrent chemoradiation therapy.

Authors:  Jin-Tung Liang
Journal:  Ann Surg Oncol       Date:  2010-08-13       Impact factor: 5.344

7.  Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?

Authors:  René Adam; Dennis A Wicherts; Robbert J de Haas; Oriana Ciacio; Francis Lévi; Bernard Paule; Michel Ducreux; Daniel Azoulay; Henri Bismuth; Denis Castaing
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

8.  Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.

Authors:  Keisuke Uehara; Kazuhiro Hiramatsu; Atsuyuki Maeda; Eiji Sakamoto; Masaya Inoue; Satoshi Kobayashi; Yuichiro Tojima; Yuichiro Yoshioka; Goro Nakayama; Hiroshi Yatsuya; Naoki Ohmiya; Hidemi Goto; Masato Nagino
Journal:  Jpn J Clin Oncol       Date:  2013-08-09       Impact factor: 3.019

9.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

10.  Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

Authors:  Eric Van Cutsem; Josep Tabernero; Radek Lakomy; Hans Prenen; Jana Prausová; Teresa Macarulla; Paul Ruff; Guy A van Hazel; Vladimir Moiseyenko; David Ferry; Joe McKendrick; Jonathan Polikoff; Alexia Tellier; Rémi Castan; Carmen Allegra
Journal:  J Clin Oncol       Date:  2012-09-04       Impact factor: 44.544

View more
  4 in total

1.  Preoperative Prediction of Perineural Invasion Status of Rectal Cancer Based on Radiomics Nomogram of Multiparametric Magnetic Resonance Imaging.

Authors:  Yang Zhang; Jiaxuan Peng; Jing Liu; Yanqing Ma; Zhenyu Shu
Journal:  Front Oncol       Date:  2022-04-11       Impact factor: 5.738

2.  Therapeutic significance of D3 dissection for low rectal cancer: a comparison of dissections between the lateral pelvic lymph nodes and the lymph nodes along the root of the inferior mesenteric artery in a multicenter retrospective cohort study.

Authors:  Hiroaki Inoue; Kazuhito Sasaki; Hiroaki Nozawa; Kazushige Kawai; Koji Murono; Shigenobu Emoto; Yuuki Iida; Hiroaki Ishii; Yuichiro Yokoyama; Hiroyuki Anzai; Hirofumi Sonoda; Kousuke Ozaki; Shinichi Yamauchi; Kenichi Sugihara; Soichiro Ishihara
Journal:  Int J Colorectal Dis       Date:  2021-02-03       Impact factor: 2.571

3.  Risk factors and prognostic significance of lateral pelvic lymph node dissection after neoadjuvant chemoradiotherapy for rectal patients with clinically suspected lateral lymph node metastasis.

Authors:  Sicheng Zhou; Yujuan Jiang; Wei Pei; Jianwei Liang; Zhixiang Zhou
Journal:  BMC Surg       Date:  2021-12-28       Impact factor: 2.102

4.  Development and External Validation of a Preoperative Nomogram for Predicting Lateral Pelvic Lymph Node Metastasis in Patients With Advanced Lower Rectal Cancer.

Authors:  Lei Zhang; Feiyu Shi; Chenhao Hu; Zhe Zhang; Junguang Liu; Ruihan Liu; Junjun She; Jianqiang Tang
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.